UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases
UCB (EBR: UCB) announced on May 3, 2026, a definitive agreement to acquire Candid Therapeutics...
UCB
UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection
UCB (EBR: UCB) has agreed to acquire Neurona Therapeutics, a U.S.-based biotechnology company developing NRTX-1001,...
UCB Secures EU Approval for Kygevvi as First-Ever Treatment for Ultra-Rare TK2 Deficiency
UCB (EBR: UCB) announced that the European Commission (EC) has granted marketing approval under exceptional...
UCB’s Bimzelx Wins NMPA Approval for Two New Indications – IL-17A/F Dual-Target Antibody Expands into Psoriasis and Hidradenitis Suppurativa
UCB (EBR: UCB) announced National Medical Products Administration (NMPA) approval for Bimzelx (bimekizumab) in two...
Antengene Licenses ATG-201 to UCB in $1.1B+ Deal – CD19/CD3 T‑Cell Engager Targets Autoimmune Diseases
Antengene Corp., Ltd (HKG: 6996) announced a licensing agreement with UCB (EBR: UCB), granting the Belgium‑based biopharma...
UCB Wins FDA Approval for KYGEVVI in Rare Mitochondrial Disease TK2d
UCB (EBR: UCB) announced that KYGEVVI received FDA approval for the treatment of adult and...
UCB Biosciences Receives NMPA Marketing Authorization for Zilucoplan (Zilbrysq) in Adult Generalized Myasthenia Gravis
UCB S.A. (EBR: UCB), a global biopharmaceutical company, announced today that the National Medical Products...
Xgene Licenses Novel Non-Opioid Analgesic XG005 to NeuroGen for Greater China Development
Shanghai-based Xgene Pharmaceutical Inc. has entered into a licensing agreement withNeuroGen Pharma, a neurology care...
UCB’s Fenfluramine Shows Positive Results in Phase III GEMZ Study for CDKL5 Deficiency Disorder
Belgium-based biopharma UCB (EBR: UCB) announced positive results from its Phase III GEMZ study, evaluating...
UCB Announces Investment in U.S. Biologics Production Facility
Belgium-based biopharmaceutical company UCB (EBR: UCB) announced plans to invest in a cutting-edge biologics production...
UCB Launches Rystiggo in China for Generalized Myasthenia Gravis
Belgium-based biopharma UCB (EBR: UCB) announced the official market launch of Rystiggo (rozanolixizumab) in China....
UCB’s Keppra Procurement Resumed in Shanghai After Regulatory Halt
Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has issued a notification resuming the procurement of UCB’s...
Luye Pharma Launches Rotigotine Luye in UK for Parkinson’s and Restless Leg Syndrome
China-based Luye Pharma Group (HKG: 2186) announced the market launch of Rotigotine Luye in the...
UCB’s Rystiggo Approved in China for Generalized Myasthenia Gravis
Belgium-based biopharma UCB (EBR: UCB) announced that it has received marketing approval from China‘’s National...
Xtalpi’s Ailux Biologics Partners with UCB for AI-Driven Drug Discovery
Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., has announced that its subsidiary...
UCB’s Minzasolmin Fails to Meet Endpoints in ORCHESTRA Study for Early Parkinson’s
Belgium-based biopharmaceutical company UCB (EBR: UCB) has announced the disappointing results of the ORCHESTRA proof-of-concept...
UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China
Belgium based UCB (EBR: UCB) is fulfilling its commitment to enhance attention to innovative products...
CBC Group and Mubadala Acquire UCB’s Neurology and Allergy Business in China for $680 Million
Singapore-based healthcare private equity firm CBC Group and Mubadala Investment Company, a global investment company...
UCB’s Bimzelx Receives US FDA Approval for Moderate to Severe Hidradenitis Suppurativa
Belgium-based biopharmaceutical company UCB (FRA: UNC) has announced that the US Food and Drug Administration...
UCB and Biogen’s Dapirolizumab Pegol Shows Promise in Phase III SLE Study
Partners UCB (FRA: UNC) and Biogen Inc. (NASDAQ: BIIB) have announced positive results from a...